Corrigendum to “The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment.” Kidney Int. 2021;100:225–237 (Kidney International (2021) 100(1) (225–237), (S0085253820314186), (10.1016/j.kint.2020.10.046))

312 Study Group

Research output: Contribution to journalComment/debatepeer-review

Fingerprint

Dive into the research topics of 'Corrigendum to “The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment.” Kidney Int. 2021;100:225–237 (Kidney International (2021) 100(1) (225–237), (S0085253820314186), (10.1016/j.kint.2020.10.046))'. Together they form a unique fingerprint.

Medicine & Life Sciences